 1. Screening Phase This will consist of a 7-day period of time following Visit 1 in which subjects will be monitored for satisfaction of inclusionexclusion criteria. If other medications are being used for treatment of peripheral neuropathic pain, then these subjects must be on a stable dose for 30 days prior to entering the single-blind phase Visit 2. At the end of this screening phase, subjects who meet all inclusion and exclusion criteria will next enter the single-blind phase. 